BEIJING (Reuters) – Anhui Biochem Pharmaceutical’s self-developed COVID-19 treatment medicine has passed the clinical trial stages and professional reviews, and is waiting for regulatory approval to enter the market, said a statement released by China’s eastern Hefei government in Anhui province on Tuesday.

The drug is targeted at adult patients with mild to moderate COVID symptoms, the Hefei government said.

Source: Read Full Article